Breaking News
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - High diet quality associated with lower risk of death in colorectal cancer patients
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - Research provides insight into neurobiology of aggression and bullying
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
Amber-Tinted Glasses Might Get You More Sleep

Amber-Tinted Glasses Might Get You More Sleep

image_pdfDownload PDFimage_print

TUESDAY, Dec. 26, 2017 — For the tech-obsessed who use their smartphones, laptops and tablets right before bedtime, a small new study suggests that inexpensive amber-tinted glasses might guarantee sound slumber.

The glasses block the blue-wavelength light emitted from many hi-tech devices. That light suppresses the brain’s production of melatonin, a hormone that regulates sleep and wake cycles.

But in the study, researchers found that adults diagnosed with insomnia got about 30 minutes more sleep when wearing wrap-around amber lenses for two hours before bedtime.

“We expect that blue-light exposure before bedtime might contribute to sleep difficulties or exacerbate sleep problems in individuals who already experience difficulties, so we were not surprised there was an improvement in sleep quality,” said study author Ari Shechter. He’s an assistant professor of medical sciences at Columbia University Medical Center in New York City.

“These kinds of glasses are very widely available, probably for $5 to $10, although more expensive options might be available for different styles,” added Shechter, who doesn’t have a financial stake in the findings.

Insomnia symptoms such as difficulty falling or staying asleep, frequent awakening or disturbed sleep occur in as many as one-third to one-half of adults, according to background information in the study. In addition, an estimated 90 percent of Americans use light-emitting electronic devices — such as tablets, smartphones and computers — in the hour before bedtime, despite the sleep-inhibiting effects of this blue-light exposure.

In the new study, 14 adults with chronic insomnia wore wrap-around, amber-tinted glasses or clear placebo glasses for two hours before bedtime for seven consecutive nights. Four weeks later, participants repeated the process with the other set of glasses.

In addition to getting about a half-hour more sleep on nights after wearing the amber lenses, participants also reported better-quality sleep and an overall reduction in their insomnia symptoms.

A slight reduction in the time it took amber lenses-wearing participants to fall asleep was noted, though it wasn’t statistically significant. “It is possible the intervention would be more effective in speeding up time to fall asleep in individuals who have difficulty falling asleep as their chief sleep complaint,” Shechter said.

Many smartphone screens can be adjusted to emit amber instead of blue light, which would be another step toward reducing insomnia symptoms in those affected. Blue-wavelength light is also emitted from many light bulbs and LED light sources increasingly being used in homes because of their energy efficiency and cost-effectiveness, he noted.

“Now more than ever, we are exposing ourselves to high amounts of blue-wavelength light before bedtime, which may contribute to or exacerbate sleep problems,” Shechter said.

“We believe this to be an important and timely study, as it describes a safe, affordable and easily implemented intervention for insomnia,” he added.

“Avoiding exposure to light from light-emitting devices before sleep would be the best approach, but using other techniques to block the blue light can help if the devices will continue to be used,” Shechter suggested.

Dr. Raman Malhotra is a spokesperson for the American Academy of Sleep Medicine and wasn’t involved in the research. He agreed with Shechter that the research should be replicated in larger numbers of patients with insomnia, possibly over longer periods of time.

But Malhotra said some doctors are already recommending patients with insomnia wear amber-tinted glasses before bedtime, reasoning there’s little to lose.

“I look at cost or risk compared to possible benefit, and in this case I feel cost and harm are minimal compared to benefits in patients’ sleep,” said Malhotra, an associate professor of neurology at the Washington University Sleep Medicine Center in St. Louis.

“Very large portions of the population have trouble sleeping because of the light coming from their devices, and this is a very reasonable thing to use,” he added.

The study is scheduled for publication in the January issue of the Journal of Psychiatric Research.

More information

The National Sleep Foundation offers more tips for sounder sleep.

© 2017 HealthDay. All rights reserved.

Posted: December 2017

Tagged with:

About author

Related Articles